Red cell transfusion requirements (mL) ( · people aged 18 and over undergoing vascular surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Fibrin sealant changes all‐cause mortality up to 30 days compared with usual care (very low certainty).
1 finding from 1 review
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people aged 18 and over undergoing vascular surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Fibrin sealant changes risk of reoperation or repeat procedure for bleeding within 7 days compared with usual care (very low certainty).
1 finding from 1 review
Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with acetylsalicylic acid (ASA) (moderate certainty).
1 finding from 1 review
Duration of fever · people undergoing initial treatment for KD
1 finding from 1 review
Duration of hospital stay MCID: 1 day absolute difference · people undergoing initial treatment for KD
1 finding from 1 review
Fever clearance time · people undergoing initial treatment for KD
1 finding from 1 review
Incidence of any adverse effects after treatment initiation ( · people undergoing initial treatment for KD
It is very uncertain whether primary treatment with intravenous immunoglobulin (IVIG) changes incidence of any adverse effects after treatment initiation (from 30… compared with acetylsalicylic acid (ASA) (very low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing initial treatment for KD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (all‐cause) (up to 30 days) · people undergoing initial treatment for KD
1 finding from 1 review
Duration of fever · people undergoing initial treatment for KD
1 finding from 1 review
Need for extra treatment · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) showed no clear difference in need for additional treatment (up to 30 or 60 days) compared with acetylsalicylic acid (ASA) (low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing initial treatment for KD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with different infusion regimens of IVIG (moderate certainty).
1 finding from 1 review
Duration of catheter patency (days; combining participant and catheter as unit of analysis) Blood withdrawing · adults with CVCs
1 finding from 1 review
Duration of clinical symptoms: fever and rash (days) · children diagnosed with Kawasaki disease
1 finding from 1 review
Time for laboratory parameters to normalise: CRP, ESR (days) Duration: N/A · children diagnosed with Kawasaki disease
1 finding from 1 review
Length of hospital stay · children diagnosed with Kawasaki disease
1 finding from 1 review
All‐cause mortality(7‐day) · people with intermediate‐risk (submassive) APE
1 finding from 1 review